
The update adds efficacy and safety data on adults newly diagnosed with pulmonary arterial hypertension.
Independent pharmacies reported higher gross margins and higher net profits on average sales of $3.2 million, according to preliminary data from the 2004 NCPA-Pfizer Digest.





